Clinical Applicability of pCASL as a Substitute for FDG-PET in MCI and SCD Patients
Key facts
- Who runs it
- University of Milano Bicocca
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 150 people enrolled
- Started
- 3 Jun 2022
- Ended
- 1 Mar 2026
- Type of study
- Observational
- Treatments tested
- pCASL
- Record updated
- 24 March 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients with mild cognitive impairment or subjective cognitive decline according to established criteria
- Clinical Dementia Rating scale of 0 or 0.5
- Signed informed consent before study entry
Who cannot take part
- Enrollment in anti-amyloid or anti-tau drugs trials
- Known major neurological or psychiatric comorbidities
- History of substance or alcohol abuse
- Contraindication to brain MRI, FDG-PET or lumbar puncture
- Secondary causes of cognitive decline
- Known causes of cerebral brain perfusion alterations
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this observational study is to compare cerebral perfusion patterns with pseudo-continuous arterial spin labeling (pCASL) and brain metabolism patterns with fluorodeoxyglucose-position emission tomography (FDG-PET) in patients with mild cognitive impairment (MCI) and subjective cognitive decline (SCD). The main questions it aims to answer are:
Read full original descriptionShow less
* Do pCASL sequences identify hypoperfusion patterns that correlate well with FDG-PET hypometabolic patterns? * Are there differences in this correlation in terms of cerebrospinal fluid (CSF) profiles? * Can hypoperfusion patterns in pCASL predict conversion to dementia? Participants will undergo brain 3 Tesla magnetic resonance imaging (MRI), FDG-PET, lumbal puncture and blood collection to analyze amyloid beta and tau, yearly detailed neuropsychological tests for three years.
Treatments tested
- pCASL
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Applicability of Pseudo-continuous Arterial Spin Labeling as a Substitute for FDG-position Emission Tomography in MCI and SCD Patients
- Record updated
- 24 March 2026